Pfizer discontinues Trubion's TRU-015 for rheumatoid arthritis
This article was originally published in Scrip
Pfizer has discontinued development of Trubion Pharmaceuticals' TRU-015, which was in Phase II development for the treatment of rheumatoid arthritis under the companies' CD20 collaboration. However, it intends to continue development of a follow-on compound, SBI-087.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.